Dexamethasone PLGA Microspheres for Sub-Tenon Administration: Influence of Sterilization and Tolerance Studies

  1. Barbosa-Alfaro, Deyanira 12
  2. Andrés-Guerrero, Vanessa 123
  3. Fernandez-Bueno, Ivan 34
  4. García-Gutiérrez, María Teresa 4
  5. Gil-Alegre, Esther 1
  6. Molina-Martínez, Irene Teresa 123
  7. Pastor-Jimeno, José Carlos 345
  8. Herrero-Vanrell, Rocío 123
  9. Bravo-Osuna, Irene 123
  1. 1 Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group, UCM 920415, Complutense University of Madrid, 28040 Madrid, Spain
  2. 2 Departamento de Farmacia Galénica y Tecnología Alimentaria, Facultad de Farmacia, Universidad Complutense de Madrid (UCM), IdISSC, 28040 Madrid, Spain
  3. 3 Thematic Research Network in Ophthalmology (Oftared) Carlos III National Institute of Health, 28040 Madrid, Spain
  4. 4 Instituto Universitario de Oftalmobiología Aplicada (IOBA), Universidad de Valladolid, 47011 Valladolid, Spain
  5. 5 Department of Ophthalmology, Hospital Clínico Universitario of Valladolid, 47003 Valladolid, Spain
Mostra les afiliacions +
Revista:
Pharmaceutics

ISSN: 1999-4923

Any de publicació: 2021

Volum: 13

Número: 2

Pàgines: 228

Tipus: Article

DOI: 10.3390/PHARMACEUTICS13020228 GOOGLE SCHOLAR lock_openAccés obert editor

Altres publicacions en: Pharmaceutics

Resum

Many diseases affecting the posterior segment of the eye require repeated intravitreal injections with corticosteroids in chronic treatments. The periocular administration is a less invasive route attracting considerable attention for long-term therapies. In the present work, dexamethasone-loaded poly(lactic-co-glycolic) acid (PLGA) microspheres (Dx-MS) were prepared using the oil-in-water (O/W) emulsion solvent evaporation technique. MS were characterized in terms of mean particle size and particle size distribution, external morphology, polymer integrity, drug content, and in vitro release profiles. MS were sterilized by gamma irradiation (25 kGy), and dexamethasone release profiles from sterilized and non-sterilized microspheres were compared by means of the similarity factor (f2). The mechanism of drug release before and after irradiation exposure of Dx-MS was identified using appropriate mathematical models. Dexamethasone release was sustained in vitro for 9 weeks. The evaluation of the in vivo tolerance was carried out in rabbit eyes, which received a sub-Tenon injection of 5 mg of sterilized Dx-MS (20–53 µm size containing 165.6 ± 3.6 µg Dx/mg MS) equivalent to 828 µg of Dx. No detectable increase in intraocular pressure was reported, and clinical and histological analysis of the ocular tissues showed no adverse events up to 6 weeks after the administration. According to the data presented in this work, the sub-Tenon administration of Dx-MS could be a promising alternative to successive intravitreal injections for the treatment of chronic diseases of the back of the eye.

€ Mostra el finançament

Informació de finançament

Finançadors

Referències bibliogràfiques

  • 10.1016/j.ophtha.2018.04.013
  • 10.1016/S2214-109X(17)30293-0
  • 10.1007/s13346-016-0336-5
  • 10.1016/S1773-2247(13)50016-5
  • 10.18433/J3H60P
  • 10.1016/j.drudis.2019.05.031
  • 10.1016/S0142-9612(01)00291-5
  • 10.1177/0192623307310955
  • 10.1167/iovs.10-6387
  • 10.1001/archopht.125.3.309
  • 10.1001/archophthalmol.2010.21
  • 10.1016/j.ophtha.2010.03.032
  • 10.1097/ICU.0b013e3281108000
  • 10.1167/iovs.08-2969
  • 10.1016/S0169-409X(01)00200-9
  • 10.1097/00006982-200410000-00002
  • 10.1111/ceo.13702
  • 10.1002/jps.23387
  • 10.2147/LRA.S16314
  • 10.1111/aos.13448
  • Geroski, (2000), Investig. Ophthalmol. Vis. Sci., 41, pp. 961
  • 10.1080/10717544.2016.1264498
  • 10.1016/j.jddst.2020.101639
  • 10.1167/iovs.08-2920
  • 10.1016/j.biopha.2018.08.138
  • 10.1016/j.ejpb.2005.11.007
  • 10.1208/s12249-009-9226-1
  • 10.1016/S0939-6411(03)00104-8
  • 10.1016/S0168-3659(99)00118-2
  • 10.1016/j.jconrel.2004.06.004
  • 10.1002/polb.1986.090240215
  • 10.1002/polb.1986.090240214
  • Hellen, (1980)
  • 10.1016/0168-3659(87)90035-6
  • 10.1016/0168-3659(87)90034-4
  • 10.1023/A:1026464124412
  • 10.1016/S0939-6411(03)00096-1
  • 10.1016/S0142-9612(02)00615-4
  • Peppas, (2014), J. Control. Release Off. J. Control. Release Soc., 190, pp. 31
  • 10.1002/jcp.10238
  • 10.1016/j.jconrel.2015.05.279
  • 10.1016/j.preteyeres.2014.04.002
  • 10.1016/j.biomaterials.2017.02.006
  • 10.1016/j.jconrel.2004.01.011
  • 10.1016/S0168-3659(98)00170-9
  • 10.1080/02713680600719036
  • 10.1167/iovs.05-0531
  • 10.2147/OPTH.S15783
  • 10.2217/fmb.11.73
  • 10.1016/0002-9394(76)90669-3
  • Mohan, (1989), Indian J. Ophthalmol., 37, pp. 13
  • 10.1016/j.ejphar.2005.02.019
  • Veloso, (1997), Investig. Ophthalmol. Vis. Sci., 38, pp. 665
  • 10.1002/jbm.820190315